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EZH2 and the Risk of Lung Cancer
Kyong-Ah Yoon, MD, Hye Jin Gil, MS, Jihye Han, MS, Jaehee Park, MS, and Jin Soo Lee, MD
Introduction: Polycomb group (PcG) proteins play essential roles
in cellular memory systems and as cell cycle regulators by main-
taining homeotic genes in their silenced states. EZH1 and EZH2, the
human homologues of the Drosophila gene Enhancer of Zeste
(E(z)), are defined as PcG proteins and contain a highly conserved
motif, called the SET (Su(var)3–9, Enhancer of Zeste, Trithorax)
domain, which is required for histone methyltransferase activity.
Increased expression of the transcriptional repressor EZH2 has been
reported to be associated with poor prognosis in various malignan-
cies including breast cancer and prostate cancer. Altered expression
of EZH2 was also demonstrated in lung cancer, suggesting an
involvement in the progression of lung cancer.
Methods: All 41 polymorphisms in EZH2 were genotyped in 335
patients with lung cancer and 335 age- and gender-matched healthy
controls. Finally, 26 polymorphisms were selected for the statistical
analysis based on minor allele frequency (0.05) and linkage
disequilibrium.
Results: Two polymorphisms of EZH2, rs6950683 and rs3757441,
showed a statistically significant association with reduced risk of
lung cancer (adjusted OR aOR  0.71, p  0.007; aOR  0.73,
p  0.015, respectively). Two copies of a haplotype (Ht2) of EZH2
also showed a significant association with reduced lung cancer risk
(aOR  0.45, 95% confidence interval  0.23–0.87).
Conclusion: This is the first study to show a significant association
between polymorphisms of the PcG gene EZH2 and lung cancer
risk. This study suggests a correlation between the genotype variants
in EZH2 and reduced lung cancer risk and hence presents a possible
marker for lung cancer susceptibility.
Key Words: EZH2, Single nucleotide polymorphism, Lung cancer,
Polycomb group.
(J Thorac Oncol. 2010;5: 10–16)
Lung cancer is the most common cancer and also theleading cause of cancer death throughout the world. Al-
though cigarette smoking is a well-known risk factor for lung
cancer, genetic diversity plays an important role in individual
susceptibility to lung cancer following exposure to tobacco
carcinogens.1,2 Common polymorphisms of phase I and II
enzymes and DNA repair enzymes have been studied to
elucidate their correlations with lung cancer susceptibility
because of the ability of these enzymes to modify the effect
of tobacco carcinogens.3–7 Polymorphisms in genes encoding
nicotine acetylcholine receptors were recently identified as
genetic risk factors for lung cancer.8–11 In addition, the
possible association of cancer susceptibility and genetic vari-
ations in the genes involved in histone modification has been
investigated.12–15 Recently, an association was reported be-
tween cancer and a polymorphism of SMYD3, a histone H4
lysine 4-specific methyltransferase.12 Cebrian et al.13 reported
a preliminary observation regarding the association of breast
cancer with variants of DNA methyltransferase and histone
methyltransferases (HMTs). We also reported the lung cancer
risk associated with polymorphisms of HMTs such as
SUV39H2 and RIZ.14,15
EZH2 is a human homolog of the Drosophila enhancer
of zeste homolog 2 (ezh2) and is also a member of the family
of SET (Su(var)3–9, Enhancer of Zeste, Trithorax) domain
proteins.16,17 The EZH2 gene is located on human chromo-
some 7q36 and has two isoforms with different transcript
sizes.18 EZH2 is a polycomb group protein that plays an
important role in the regulation of gene repression at the
chromatin level by mediating the methylation of lysine 27 in
histone H3.19–21 EZH2 has been reported to be involved in
oncogenesis by interacting with regulators of cell prolifera-
tion such as E2Fs, pRB, and cyclin A.22,23 Overexpression of
EZH2 was reported in metastatic prostate cancer and was
found to be associated with a poor prognosis among patients
with prostate cancer.24 Consistent with the growth-stimulat-
ing effect of EZH2, knockdown of EZH2 expression inhib-
ited the proliferation of prostate cancer cells. Similar results
were also reported in multiple myeloma cells, and the onco-
genic activity of EZH2 required HMT activity.25 Recently,
altered expression levels of EZH2 and its role in disease
progression were demonstrated in various cancers, such as
breast cancer, pancreatic cancer, and gastric cancer.26–28 The
role of EZH2 in tumor aggressiveness was related to the
repression of several target genes such as E-cadherin,
RUNX3, and PSP94 by trimethylation of H3K27.29–31 Based
on its functional significance and its dysregulated expression
pattern in malignancies, the genetic variations in the EZH2
gene could be associated with cancer susceptibility.
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To test the hypothesis that genetic polymorphisms of
the EZH2 gene are associated with the risk of lung cancer, we




This study was a hospital-based case-control study.
Three hundred thirty-five cases were recruited from patients
with histologically confirmed lung cancer who visited the
National Cancer Center in Korea and voluntarily participated
in a questionnaire survey conducted from May 2002 to July
2003. The subjects donated blood for genetic tests after
signing the informed consent form, which had been approved
by the institutional review board. There were no recruitment
restrictions with regard to gender or cancer stage, but only
subjects who were younger than 70 years were recruited.
None of these cancer patients had received chemotherapy or
radiotherapy before their recruitment. As a control group, a
total of 335 control subjects were matched with patients with
lung cancer for age (3 years) and gender. These control
subjects without a history of cancer were recruited from patients
who visited our institution for a cancer screening program.
Information on demographic characteristics such as gender, age,
smoking habits, and family history of cancer were obtained from
self-administered questionnaires (for controls) or a personal
interview (for cases) administered by trained personnel after
written informed consent was obtained.
Genotyping of EZH2 Polymorphisms
A total of 41 single nucleotide polymorphisms (SNPs)
of the EZH2 gene (NM_004456) were selected from the
International HapMap Project data (www.hapmap.org) for
this study. Genomic DNA was extracted from the peripheral
blood using a QIAamp DNA Blood Mini Kit (Qiagen, Va-
lencia, CA) in accordance with the manufacturer’s instruc-
tions. The highly multiplexed SNP GoldenGate genotyping
assay (Illumina Inc., San Diego, CA) was performed, which
combines oligonucleotide ligation with an allele-specific ex-
tension reaction.32
Statistical Analysis
To test for the differences in demographic characteris-
tics between lung cancer cases and controls, Pearson’s 2 test
was used for categorical variables, and the Wilcoxon rank
sum test was used for continuous variables. With regard to
smoking habits, smoking status, the number of cigarettes
smoked per day, and the time of starting and quitting were
investigated. Individuals who had either formerly smoked
more than 100 cigarettes during their lifetime or currently
smoked were defined as ever smokers. As a measure of
cumulative smoking exposure, pack-years were defined as the
average number of packs (20 cigarettes/pack) of cigarettes
smoked per day multiplied by the total number of years of
smoking.
The Hardy-Weinberg equilibrium (HWE) was tested
for the control genotyping results. A p level 0.01 was
accepted as statistically significant for the HWE test. If a
polymorphism was not in HWE (P  0.01), it was excluded
from further analysis.
We employed a widely used measure of linkage dis-
equilibrium (LD) between all pairs of biallelic loci, Le-
wontin’s D ( D ), and r2.33 LD blocks were identified using
Haploview software.34 Haplotypes of each block and individ-
ual were inferred using the algorithm developed by Stephens
et al. (PHASE),35 which uses a Bayesian approach to incor-
porate a priori expectations for haplotype reconstruction.
Phase probabilities for each site were calculated for each
individual by this software, and the haplotype with the high-
est probability for each sample was used for further analysis.
The genetic effects of inferred haplotypes were analyzed in
the same way as SNPs. The relationship between EZH2
polymorphisms and lung cancer risk was analyzed using
unconditional multiple logistic regression models while con-
trolling for family history, pack-years, and smoking status as
covariates. We also analyzed the association between EZH2
polymorphisms and the risk of non-small cell lung cancer
(NSCLC) and small cell lung cancer (SCLC), the two distinct
histologic types in lung cancer. Analyses for the association
between haplotypes and lung cancer risk were performed
using unconditional logistic regression at the individual level,
in which the covariate was defined by the number of copies
(0, 1, or 2) of each haplotype that a subject carried, and the
model also included family history of cancer, smoking status,
and pack-years as covariates. All reported p values are two-
sided. The statistical software Stata/SE version 10 was used
for statistical analyses (StataCorp LP, College Station, TX).
RESULTS
The demographic features of patients with lung cancer
and healthy controls are shown in Table 1. Lung cancer
patients were more likely than the controls to have ever
smoked (p  0.001). The distribution of family history of
cancer was significantly different between the cases and
controls (p 0.05). Of the 335 patients with lung cancer, 189
(56%) had adenocarcinomas, 77 (23%) had squamous cell
carcinomas, and 29 (9%) had SCLC.
A total of 41 SNPs of the EZH2 gene (NM_012231)
were selected from the International HapMap Project data
and analyzed to measure the LD after genotyping (Figure
1A). A representative SNP was only selected if there were
absolute LDs (r2  1); 26 SNPs were finally selected for the
statistical analysis based on minor allele frequency and LDs.
The common haplotypes (6%) of EZH2 polymorphisms are
indicated in Figure 1B. The LD block was determined from
the results of LD analysis using the Haploview software
(Figure 1C).
Table 2 presents the minor allele frequencies of the 26
SNPs among patients with lung cancer and normal controls
and the estimated odds ratios of lung cancer risk between
subjects carrying one variant allele and subjects carrying no
variant allele of each SNP based on a multiple logistic
regression model (log-additive model) controlling for smok-
ing status, pack-years, and the family history of cancer as
covariates.
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FIGURE 1. Gene maps, haplotypes, and linkage disequilibriums (LDs) of EZH2 single nucleotide polymorphisms (SNPs).
Coding exons are marked by black blocks and 5 and 3 UTRs by white blocks. The first base of the translational start site
is denoted as nucleotide 1. Asterisks indicate the SNPs that were used for the statistical analysis. A, SNPs genotyped in
the study subjects. The frequencies of the SNPs were based on findings in 670 subjects (335 patients with lung cancer
and 335 normal controls). B, Five common haplotypes of EZH2 with a frequency of 0.06. C, LD block in EZH2 identi-
fied using Haploview.
TABLE 1. Demographic Characteristics of Patients with Lung Cancer and Normal Controls
Phenotype Normal Controls (n  335)
Lung Cancer Cases
All (n  335) NSCLC (n  306) SCLC (n  29)
Age (median, range) 58 (28–73) 58 (25–70) 58 (25–70) 60 (37–70)
Gender (n, %)
Male 226 (67.5%) 226 (67.5%) 204 (66.7%) 22 (75.9%)
Female 109 (32.5%) 109 (32.5%) 102 (33.3%) 7 (24.1%)
Smoking status (n, %)a
Never smoker 139 (41.5%) 116 (34.6%) 112 (36.6%) 4 (13.8%)
Ever smoker 189 (56.4%) 218 (65.1%) 193 (63.1%) 25 (86.2%)
Current 86 (25.7%) 143 (42.7%) 123 (40.2%) 20 (69.0%)
Former 103 (30.7%) 75 (22.4%) 70 (22.9%) 5 (17.2%)
Unknown 7 1 1
Pack-years (median, range)b 21 (0.3–126) 34.5 (0.08–135) 34.75 (0.08–135) 34 (0.35–114)
Family history (n, %)a
Yes 166 (49.6%) 128 (38.3%) 119 (38.9%) 9 (31.0%)
No 167 (49.9%) 205 (61.4%) 185 (60.5%) 20 (69.0%)
Unknown 2 2 2
a p  0.05 in Pearson’s 2 test for the difference between lung cancer patients and controls.
b Pack-years of smoking were calculated for ever smokers only. p  0.05 in Wilcoxon rank sum test for the difference between lung cancer
patients and control.
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
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Among 26 SNPs, the variant genotypes of rs6950683
and rs3757441 showed a significant association with reduced
lung cancer risk (adjusted OR aOR  0.71, 95% confidence
interval CI  0.55–0.91, p  0.007 and aOR  0.73, 95%
CI  0.57–0.94, p  0.015, respectively). Subset analyses
were performed for the NSCLC group and the SCLC group
based on histologic cell type. The association with a de-
creased risk of lung cancer was much stronger in the SCLC
group than in the NSCLC group (aOR  0.40, 95% CI 
0.19–0.83, p  0.014 and aOR  0.41, 95% CI  0.20–
0.85, p  0.017). Specifically, rs41277434 was associated
with an increased risk of SCLC even though the sample size
for SCLC was limited (aOR  2.76, p  0.021). The effects
of rs6950683, rs3757441, and rs41277434 were further ana-
lyzed using alternative models such as codominant, domi-
nant, and recessive models (Table 3). The effect of rs6950683
on lung cancer risk was also analyzed in adenocarcinoma group
and never-smokers group (aOR  0.81, p  0.16 and aOR 
0.81, p 0.32, respectively). Lung cancer risk was decreased in
both groups, however, it was not statistically significant. The
genotype distribution of rs6950683 was not different between
ever smokers and never smokers (p  0.73).
From 26 SNPs of the EZH2 gene, five common haplo-
types (6% frequency) were identified with a cumulative
frequency of 91% in the controls (Figure 1B). The common
haplotypes were labeled and categorized as Ht1 to Ht5 based
on their computer-estimated frequency, and other rare haplo-
types were grouped together in the analyses as shown in
Table 4. Subjects carrying two copies of Ht2 haplotype
showed a significantly decreased risk of lung cancer (aOR 
0.45, 95% CI  0.23–0.87).
DISCUSSION
Polymorphisms of the EZH2 gene showed a significant
association with lung cancer in this case-control study. EZH2
is a polycomb group protein containing a SET domain that
has HMT activity. Increased expression of EZH2 was re-
ported along with a growth-stimulating effect and increased
tumor aggressiveness in various cancers.26–29 The functional













(n  29) OR (95% CI) p OR (95% CI) p OR (95% CI) p
rs6950683 5 near
gene
G:A 0.3 0.246 0.243 0.155 0.71 (0.55–0.91) 0.007 0.74 (0.57–0.95) 0.021 0.40 (0.19–0.83) 0.014
rs2177567 Intron 1 C:T 0.479 0.518 0.516 0.534 1.19 (0.95–1.48) 0.122 1.17 (0.94–1.47) 0.154 1.39 (0.78–2.45) 0.261
rs1880357 Intron 1 G:C 0.167 0.173 0.172 0.190 1.01 (0.75–1.34) 0.960 1.01 (0.75–1.35) 0.968 1.06 (0.52–2.15) 0.882
rs1880358 Intron 1 T:C 0.354 0.309 0.312 0.276 0.82 (0.65–1.03) 0.093 0.83 (0.65–1.05) 0.124 0.68 (0.37–1.24) 0.208
rs10233740 Intron 1 T:C 0.354 0.310 0.314 0.276 0.82 (0.65–1.04) 0.105 0.84 (0.66–1.06) 0.139 0.68 (0.37–1.24) 0.208
rs1880355 Intron 1 T:A 0.354 0.310 0.314 0.276 0.82 (0.65–1.04) 0.102 0.83 (0.66–1.06) 0.136 0.68 (0.37–1.24) 0.208
rs10952780 Intron 1 A:C 0.479 0.516 0.515 0.534 1.18 (0.95–1.47) 0.133 1.17 (0.94–1.47) 0.168 1.38 (0.78–2.45) 0.261
rs6975291 Intron 1 G:C 0.354 0.312 0.315 0.276 0.83 (0.66–1.05) 0.115 0.84 (0.66–1.07) 0.153 0.68 (0.37–1.24) 0.208
rs9691534 Intron 1 C:T 0.352 0.312 0.315 0.276 0.84 (0.66–1.06) 0.132 0.85 (0.67–1.08) 0.174 0.68 (0.37–1.26) 0.220
rs28723387 Intron 2 G:A 0.169 0.173 0.172 0.190 1.00 (0.75–1.33) 0.990 1.00 (0.74–1.34) 0.984 1.05 (0.52–2.15) 0.887
rs6959647 Intron 3 C:T 0.352 0.310 0.314 0.276 0.83 (0.66–1.05) 0.118 0.84 (0.66–1.07) 0.155 0.68 (0.37–1.26) 0.220
rs10488070 Intron 4 T:C 0.169 0.178 0.176 0.190 1.03 (0.77–1.37) 0.858 1.03 (0.77–1.38) 0.851 1.02 (0.51–2.06) 0.946
rs2302427 Exon 6 G:C 0.082 0.079 0.08 0.069 0.95 (0.64–1.41) 0.806 0.97 (0.65–1.45) 0.886 0.77 (0.25–2.35) 0.648
rs3757441 Intron 6 T:C 0.296 0.237 0.245 0.155 0.73 (0.57–0.94) 0.015 0.77 (0.59–0.99) 0.038 0.41 (0.20–0.85) 0.017
rs1061037 Intron 8 A:C 0.167 0.173 0.172 0.190 1.00 (0.75–1.34) 0.974 1.00 (0.75–1.35) 0.979 1.03 (0.51–2.07) 0.934
rs6464926 Intron 8 C:T 0.478 0.509 0.507 0.534 1.15 (0.92–1.43) 0.211 1.13 (0.91–1.42) 0.267 1.39 (0.79–2.44) 0.251
rs17171119 Intron 8 T:G 0.173 0.181 0.18 0.190 1.03 (0.78–1.37) 0.826 1.04 (0.78–1.39) 0.809 1.01 (0.50–2.03) 0.979
rs17551792 Intron 10 C:T 0.057 0.060 0.057 0.086 1.02 (0.64–1.64) 0.919 0.99 (0.61–1.60) 0.964 1.57 (0.55–4.47) 0.394
rs3735219 Intron 12 G:A 0.154 0.163 0.16 0.190 1.03 (0.77–1.40) 0.829 1.03 (0.75–1.39) 0.873 1.25 (0.59–2.62) 0.559
rs2072407 Intron 15 C:T 0.354 0.307 0.31 0.276 0.81 (0.64–1.02) 0.078 0.82 (0.65–1.04) 0.104 0.68 (0.37–1.24) 0.207
rs41277434 Intron 18 T:G 0.057 0.066 0.059 0.138 1.13 (0.72–1.78) 0.591 1.01 (0.63–1.64) 0.954 2.76 (1.16–6.53) 0.021
rs740949 Intron 19 G:A 0.352 0.307 0.31 0.276 0.82 (0.65–1.03) 0.090 0.83 (0.65–1.05) 0.118 0.68 (0.37–1.26) 0.225
rs734005 Intron 19 T:C 0.352 0.309 0.312 0.276 0.82 (0.65–1.04) 0.097 0.83 (0.66–1.06) 0.129 0.68 (0.37–1.24) 0.209
rs734002 Intron 19 G:A 0.354 0.309 0.312 0.276 0.82 (0.65–1.03) 0.088 0.83 (0.65–1.05) 0.118 0.68 (0.37–1.24) 0.207
rs734004 Intron 19 G:C 0.355 0.309 0.312 0.276 0.81 (0.64–1.02) 0.078 0.82 (90.65–1.04) 0.106 0.67 (0.37–1.24) 0.204
rs887569 Intron 19 A:G 0.355 0.310 0.314 0.276 0.82 (0.65–1.03) 0.089 0.83 (0.65–1.05) 0.120 0.67 (0.37–1.24) 0.204
The ORs (95% CI) and corresponding p values were estimated from a log-additive model using unconditional multiple logistic regression, controlling for family history, smoking
status, and pack-years as covariates. p values under 0.05 are indicated in bold font.
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; CI, confidence interval.
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significance and altered expression level of EZH2 make it
feasible to evaluate the association between the gene’s poly-
morphisms and cancer susceptibility.
In this hospital-based case-control study, 41 polymor-
phisms of EZH2 were genotyped in 335 patients with lung
cancer and 335 healthy controls. Controls recruited among
the cancer screenees at our hospital showed a higher preva-
lence of a family history of cancer than did the lung cancer
cases. Therefore, the association between the SNPs and the
risk of lung cancer was analyzed by controlling for family
history of cancer, as well as other potential confounding
variables such as smoking status and pack-years. Two poly-
morphisms of EZH2, rs6950683 and rs3757441, showed a
protective effect on lung cancer risk. The reduced lung cancer
risk associated with two polymorphisms was significant in the
NSCLC group as well as in the SCLC group. Although the
NSCLC and SCLC groups present different demographic
features, as shown in Table 1, the protective effect of EZH2
polymorphisms was demonstrated in both of these distinct
histologic types. Even though the number of patients with
SCLC (n  29) was much smaller than that of NSCLC
patients (n  306), the SCLC group had more men and more
current smokers than the NSCLC group.
In the case of rs41277434, although an increased risk of
lung cancer was observed in the SCLC group, the sample size
was not sufficient to compare with those of the control group.
Because rs6950683 is located near exon 1, it may
impact gene expression by affecting the promoter region.
However, further biologic and/or functional evidence is
needed to confirm the genetic effects of EZH2 polymor-
phisms on lung cancer.
Because EZH2 is known as a polycomb group gene that
plays an important role in cell cycle regulation, it can be
hypothesized that EZH2 polymorphisms have a significant
association with other cancers besides lung cancer. Recently,
EZH2 mediated histone H3 lysine 27 trimethylation was
reported as a mechanism of tumor suppressor gene silenc-
ing.36 Overexpressed EZH2 was associated with poor prog-
nosis and EZH2 knockdown induced increase of target genes
involved in cell growth and differentiation.20,36 Because of its
HMT activity with substrate specificity for histone H3 lysine
27, the genetic variations in the EZH2 gene could be associ-
TABLE 3. Association of Three Polymorphisms of EZH2 with Lung Cancer Risk According to Histologic Type in Patients with
Lung Cancer
SNP Genotype
Frequency Codominant Model Dominant Model Recessive Model
Controls LC OR (95% CI) p OR (95% CI) p OR (95% CI) p
Overall rs6950683 GG 166 194 1 1 1
AG 137 124 0.77 (0.55–1.06) 0.108 0.70 (0.52–0.96) 0.027
AA 32 17 0.44 (0.23–0.83) 0.012 0.49 (0.26–0.92) 0.026
rs3757441 TT 169 193 1 1 1
CT 134 125 0.81 (0.58–1.12) 0.202 0.74 (0.54–1.01) 0.058
CC 32 17 0.45 (0.24–0.85) 0.014 0.49 (0.26–0.92) 0.026
rs41277434 TT 298 293 1 1 1
GT 36 40 1.09 (0.67–1.77) 0.733 1.12 (0.69–1.80) 0.656
GG 1 2 2.09 (0.18–23.91) 0.554 2.07 (0.18–23.67) 0.56
NSCLC rs6950683 GG 166 174 1 1 1
AG 137 115 0.79 (0.57–1.10) 0.162 0.73 (0.53–1.01) 0.055
AA 32 17 0.49 (0.26–0.93) 0.03 0.54 (0.29–1.01) 0.056
rs3757441 TT 169 173 1 1 1
CT 134 116 0.83 (0.60–1.16) 0.286 0.77 (0.56–1.06) 0.109
CC 32 17 0.50 (0.26–0.96) 0.036 0.54 (0.29–1.01) 0.056
rs41277434 TT 298 271 1 1
GT 36 34 1.00 (0.60–1.66) 0.996 1.01 (0.61–1.66) 0.979
GG 1 1 1.32 (0.08–21.58) 0.846 1.32 (0.08–21.57) 0.846
SCLC rs6950683 GG 166 20 1 1 1
AG 137 9 0.54 (0.23–1.27) 0.182 0.41 (0.18–0.95) 0.038
AA 32 0
rs3757441 TT 169 20 1 1 1
CT 134 9 0.56 (0.24–1.31) 0.182 0.42 (0.18–0.98) 0.044
CC 32 0
rs41277434 TT 298 22 1 1 1
GT 36 6 2.30 (0.83–6.34) 0.109 2.66 (1.01–6.98) 0.047
GG 1 1 19.27 (0.95–390.79) 0.054 16.89 (0.85–333.86) 0.063
Corrected p values were obtained using the correction for multiple tests. The ORs (95% CI) and corresponding p values were derived from a logistic analysis controlling for
smoking status, pack-years, and family history as covariates. Odds ratios that are statistically significant (p  0.05) are indicated in bold font.
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; CI, confidence interval; LC, lung cancer cases.
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ated with diversity of enzymatic activity and cancer suscep-
tibility. Further epidemiologic studies in larger populations
are required to test this hypothesis.
Despite the important discovery of a protective effect of
the EZH2 polymorphisms, this study only considers a Korean
population, which may limit the application of these findings
to other ethnic populations. Furthermore, the subset analysis
according to histologic type was limited by sample size,
particularly for SCLC.
In conclusion, this is the first study to show a significant
association between polymorphisms of the EZH2 gene and
lung cancer risk. These results suggest that the presence of
the variant allele in EZH2 may be a protective factor for the
development of lung cancer and could be a marker associated
with genetic susceptibility to lung cancer.
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